Navigation Links
Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
Date:12/19/2007

ate the safety and tolerability of treatment with Amigal. The secondary objective was to evaluate certain pharmacodynamic measures of treatment, including effects on a-GAL (the target enzyme deficient in Fabry patients) and levels of GL-3 (the substrate that builds up in the cells of patients) in cells and tissues affected by the disease. An additional objective was the preliminary assessment of cardiac and renal function.

The four open-label, multi-national Phase 2 trials of Amigal enrolled 18 men and 9 women with Fabry disease between the ages of 17 and 65. The four studies examined various dose levels and frequencies of Amigal administration and had 12 or 24 week primary treatment arms with an optional treatment extension.

Twenty-six patients completed the primary treatment arms and all entered the optional treatment extension. The 26 patients had 21 different missense genetic mutations that cause Fabry disease. The mutations represented the full spectrum of Fabry patients, including those with both early-onset and late- onset forms of the disease. Twenty-three patients are currently being treated with Amigal under the treatment extension, including 8 who have been treated for more than a year and 4 who have been treated for almost 2 years.

"The positive results of these first trials of a pharmacological chaperone in Fabry disease are impressive," said Raphael Schiffmann, M.D., Lead Investigator at the Metabolic Neurology Branch of the National Institute of Neurological Disorders and Stroke (NINDS), a part of the National Institutes of Health, and a principal investigator in one of the Amigal clinical trials. "I believe this technology has the potential to be an important new treatment option for many Fabry disease patients."

The key findings in the Phase 2 studies were:

* Amigal was generally safe and well-tolerated at all doses evaluated. No

drug-related serious adverse events were reported during the primary


'/>"/>
SOURCE Amicus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Biofeedback – When a behavioral ... selecting medication to best treat it can become a ... using electroencephalography (EEG) can help predict which medicine will ... of adverse drug events. , The article “Medication ... current issue of the journal Biofeedback offers evidence that ...
(Date:7/21/2014)... California (PRWEB) July 21, 2014 ... County Workforce Investment Board (WIB) and Las Positas ... to provide technical education and hands-on training for ... Engineering Technology Program at Las Positas is ... training needed for engineering technician careers, and establishes ...
(Date:7/21/2014)... Syracuse University,s College of Arts and Sciences has ... of stainless nanoparticles. , Mathew M. Maye, associate ... $360,000 grant from the National Science Foundation (NSF). ... stainless alloy nanostructures, the results of which may ... batteries. , Maye,s approach is novel, ...
(Date:7/21/2014)... New York , July 21, 2014 /PRNewswire/ ... research on Global & USA ... Size, Trends, and Forecasts ResearchMoz presents ... Cancer Biomaker Market   to 2018 (Identification, Technologies, Market ... Industry Trends, and Pipeline Analysis. GLOBAL ...
Breaking Biology Technology:Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 2Analyzing Brain Patterns with EEG Can Help Predict Effective Use of Medication 3Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3Syracuse University chemist to use NSF grant to study materials chemistry, nanoscience 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 2Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 3Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 4Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 5Global & USA Cancer Biomaker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis) - Market Size, Trends, and Forecasts A 6
... May 24, 2011 Benefiting from recent investments in production ... just reported another record quarter. The leading developer of topical ... up 126 percent over Q1 of 2010. It was the ... year ago. "Although Q1 delivered a stellar ...
... 2011 Radius Health, Inc. ("Radius") today announced that ... third financing round, including $66 million in equity financing ... and Oxford Finance LLC to a $25 million multi-draw ... AG, Brookside Capital, Saints Capital, Nordic Bioscience ("Nordic"), and ...
... A protein isolated from beneficial bacteria found in yogurt ... option for inflammatory bowel disorders (IBD), suggests a study ... M.D., Ph.D. The study, published May 23 in ... the protein, called p40, was effective as an intervention ...
Cached Biology Technology:First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 2First-quarter 2011 Sales Reach $2.25M — 126% Growth Over Q1 of 2010 — for Biotech Developer Divine Skin 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 2Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 3Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 4Radius Announces Closing of $91 Million Financing to Advance BA058 Injection into Phase 3 Osteoporosis Study 5Protein from probiotic bacteria may alleviate inflammatory bowel disorders 2Protein from probiotic bacteria may alleviate inflammatory bowel disorders 3
(Date:7/22/2014)... box and you,re likely to find that the lunches and ... findings of a study conducted by researchers at the Friedman ... in the Department of Public Health and Community Medicine at ... online ahead of print in the Journal of the ... senior author Jeanne Goldberg, Ph.D., R.D., a professor at the ...
(Date:7/22/2014)... 22, 2014, Cleveland: A type of immune cell ... such as Alzheimer,s disease and multiple sclerosis (MS), ... injury (TBI) and may slow the progression of ... today in the online journal Nature Communications ... Trapp, PhD, Chair of the Department of Neurosciences ...
(Date:7/21/2014)... Middle East Respiratory Syndrome coronavirus (MERS-CoV) in the air ... virus. The work, published this week in mBio ... for Microbiology, indicates that further studies are needed to ... air. , MERS, a serious viral respiratory illness caused ... as of June 11, according to the World Health ...
Breaking Biology News(10 mins):Room for improvement in elementary school children's lunches and snacks from home 2Cleveland Clinic researchers discover neuroprotective role of immune cell 2Middle East Respiratory Syndrome coronavirus detected in the air of a Saudi Arabian camel barn 2
... complaint against British drug maker GlaxoSmithKline (GSK) over its ... proceed following an order late last week by South ... go forward. GSK has sought outright dismissal of the ... week giving the complainants, AIDS Healthcare Foundation (AHF) and ...
... apples might do a better job of keeping the ... analyzed eight popular varieties of the fruit. Red Delicious, ... greater wallop of disease-fighting antioxidants than other apples studied. ... Agriculture and Agri-Food Canada in Guelph, Ontario, also pinpointed ...
... of an anti-inflammatory drug eliminated all of the cancer-causing ... when several genetic brakes to cancer formation were missing ... Cancer Center. , The investigators, who presented their findings ... for Cancer Research, say that while the results do ...
Cached Biology News:South African Tribunal Asks For Damages Estimates in GSK AIDS Drug Case 2Red delicious, Northern Spy apples have most antioxidants, chemists find 2NSAID drug protects against intestinal tumors in mice, despite poor diet and gene losses 2NSAID drug protects against intestinal tumors in mice, despite poor diet and gene losses 3
... muscle cell specific protein, is reported to be ... as intestine, lung and uterus. It shares structural ... expression has been reported in most tissues that ... forms. It is also reported to be expressed ...
PC based system for superior chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Request Info...
... Round Well Plate Sterile ... wide range of 384-well ... high-throughput screening and research. ... assays and are suitable ...
Biology Products: